ArticleBMC pediatrics2026
Liver transplant for paediatric acute liver failure: insights from a newly established paediatric liver transplant program in a developing country.
Article in BMC pediatrics, 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
0 citing papers in PubMed.
No citing paper in PubMed yet.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
11 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
backgroundLiver transplantation (LT) is the cure for medically refractory acute liver failure (ALF). In resource-limited settings, establishing a paediatric LT program for paediatric ALF (PALF) encounters unique challenges.
methodsThis study describes the initial 5-year experience of the paediatric LT (PLT) program at the Colombo North Centre for Liver Diseases (CNCLD), Sri Lanka (March 2020 to March 2025). Data from all PALF cases (n = 35) were retrospectively analyzed.
resultsA total of 120 children were referred to LT and 35 (29%) were due to ALF. Median age was 8 years 9 months (range: 2 months - 13 years) and 63% were male. Common etiologies included Wilson disease (23%) and autoimmune liver disease (20%). Spontaneous recovery occurred in 43% (15) while 34% (12/35) underwent LT and 23% (8) died without LT. Of 12 transplant recipients, 8/12 received living donor liver transplants (LDLT) (5/8 related donors, 3/8 altruistic - Buddhist monks), and 4/12 received deceased donor liver transplants (DDLT). The median time from listing to transplant was 72 h. Post-transplant survival in one and three months was 75% and 66% respectively. There were three immediate post-LT deaths due to primary non-function of deceased donor grafts.
conclusionPALF comprised a substantial proportion of referrals in Sri Lanka's nascent PLT program. The majority of LT for PALF were LDLT with favorable outcomes compared to DDLT. Optimum utilization of a budding LT program with timely referrals and availability of altruistic donors have played key roles in the success of the PLT program in a resource limited setting.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.